Volume 11,Issue 1
The Application Value of Shexiang Baoxin Pills in the Treatment of Microcirculation Disorders after Coronary Intervention
Objective: To explore the practical application value of Shexiang Baoxin Pills in the treatment of microcirculation disorders after coronary intervention. Methods: 60 patients who developed microcirculation disorders after undergoing coronary intervention in the hospital from May 2022 to May 2025 were selected and divided into a conventional group and an observation group using the random number table method, with 30 cases in each group. The conventional group only adopted the conventional treatment plan after coronary intervention, and the observation group added Shexiang Baoxin Pills on the basis of conventional treatment. The therapeutic effects of the two groups were compared. Results: Compared with the conventional group, the observation group had better improvement in cardiac function-related indicators, higher overall treatment effectiveness, and lower complication rate (P<0.05). Conclusion: In the treatment of patients with microcirculation disorders after coronary intervention, the addition of Shexiang Baoxin Pills can effectively improve the patients’ cardiac function indicators, enhance the treatment effect, and reduce complications, and has high clinical application value.
[1] Zhang CW, Lin YH, Deng JX, 2024, Effect of Shexiang Baoxin Pills Combined with Valsartan and Amlodipine Tablets in the Treatment of Coronary Heart Disease Angina Pectoris. Chinese Journal of Drug Abuse Prevention, 30(12): 2334–2335.
[2] Wang KL, 2024, Effect of Shexiang Baoxin Pills on Coronary Blood Flow and Heart Rate Variability in Patients with Coronary Heart Disease and Angina Pectoris. Chinese and Foreign Medical Research, 22(32): 41–45.
[3] Deng HX, Han XW, Wang DY, et al., 2024, Meta-Analysis of the Efficacy of Chinese Patent Medicines in the Treatment of Microvascular Angina. World Journal of Integrated Traditional Chinese and Western Medicine, 19(10): 1949–1957 + 1962.
[4] Liu Z, Xiong RD, 2024, The Application Effect of Shexiang Baoxin Pills Combined with Aspirin and Clopidogrel in Patients with Cold Coagulation Syndrome After Percutaneous Coronary Intervention for Acute Coronary Syndrome. Chinese Contemporary Medicine, 31(28): 102–105.
[5] Xiang N, Liu BL, Wu B, et al., 2024, Research Progress on Shexiang Baoxin Pills in the Treatment of Ischemia-Related Arrhythmias. Chinese Journal of Cardiac Pacing and Cardiac Electrophysiology, 38(6): 402–406.
[6] Feng LH, 2024, Observation on the Effects of Shexiang Baoxin Pills Combined with Metoprolol on Blood Lipid Levels and Inflammatory Response in Community-Based Patients with Coronary Heart Disease and Angina Pectoris. Modern Diagnosis and Treatment, 35(17): 2576–2578.
[7] Liao PF, Zong XJ, 2024, Study on the Clinical Value of Shexiang Baoxin Pills Combined with Atorvastatin in the Treatment of Acute Myocardial Infarction. Modern Diagnosis and Treatment, 35(16): 2385–2387.
[8] Wang ZJ, Lu DM, Zhang GJ, et al., 2024, Pharmacoeconomic Evaluation of Shexiang Baoxin Pills and Tongxinluo Capsules in the Treatment of Angina Pectoris in Patients with Coronary Atherosclerotic Heart Disease. Chinese Pharmacoeconomics, 19(8): 30–37 + 43.
[9] Dong KZ, Lin XP, Chen CW, 2024, The Efficacy of Shexiang Baoxin Pills Combined with Atorvastatin in the Treatment of Patients with Acute Coronary Syndrome and Its Effect on Blood Lipids, Serum MMP-8 and TIMP-1. General Medicine Clinical and Education, 22(7): 620–623.
[10] Li C, Kang ZK, Lu WH, et al., 2024, Pharmacoeconomic Evaluation of Shexiang Baoxin Pills and Suxiao Jiuxin Pills in the Treatment of Angina Pectoris in Patients with Coronary Atherosclerotic Heart Disease. Chinese Pharmacoeconomics, 19(7): 23–30 + 35.